Yes, Daxxify is FDA approved. The product received clearance on September 27, 2023, as a neuromodulator indicated for the temporary improvement of moderate to severe glabellar lines (frown lines between the eyebrows) in adults. It is manufactured by Revance Therapeutics and represents the first new botulinum toxin Type A product approved by the FDA in nearly two decades.
Injectables
Is Daxxify FDA Approved? Status, Indications, and How It Compares to Botox
Daxxify received FDA approval in September 2023 as a long-acting neuromodulator with a different formulation and duration profile than Botox.
